BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guiard E, Lelievre B, Rouyer M, Zerbib F, Diquet B, Mégraud F, Tison F, Bignon E, Lassalle R, Droz-Perroteau C, Moore N, Blin P. Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study. Drug Saf 2019;42:993-1003. [PMID: 31069703 DOI: 10.1007/s40264-019-00821-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang C, Li X, Cheng T, Sun H, Jin L. Eradication of Porphyromonas gingivalis Persisters Through Colloidal Bismuth Subcitrate Synergistically Combined With Metronidazole. Front Microbiol 2021;12:748121. [PMID: 34745052 DOI: 10.3389/fmicb.2021.748121] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Gong M, Zhang R, Qi J, Wang J, Liu Q, Zhou H, Song Y, Song X, Mei Y. In vitro evaluation of the antibacterial effect of colloidal bismuth subcitrate on Porphyromonas gingivalis and its biofilm. Arch Oral Biol 2022;133:105300. [PMID: 34742000 DOI: 10.1016/j.archoralbio.2021.105300] [Reference Citation Analysis]
3 Blin P, Rouyer M, Guiard E, Zerbib F, Diquet B, Mégraud F, Tison F, Abouelfath A, Lassalle R, Droz-Perroteau C, Moore N. Patterns of quadruple therapy use including bismuth for Helicobacter pylori eradication: A cohort study in the French national claims database. Therapie 2021;76:435-40. [PMID: 33334580 DOI: 10.1016/j.therap.2020.09.002] [Reference Citation Analysis]
4 Kim JY, Lee SY, Kim JH, Sung IK, Park HS. Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication. Helicobacter 2020;25:e12683. [PMID: 32074663 DOI: 10.1111/hel.12683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]